novo nordisk getting slammed after 15 drugs subject to price negotiations for 2027, including novo's glp-1 drugs, ozempic and wegovy, trading at lows last seen in the summer of 2023. eli lilly shares falling in sympathy and broader concerns over pricing pressures in the glp- glp-1 category. the company trimmed 2025 guidance earlier in the week. and a wrinkle for novo, sdeeld a higher dose of wegovy, patients losing 20.7% of their body weight after 72 weeks. that's still slightly less than what patients see on existing doses of zepbound, what does this mean for the direction of the obesity trade which has come back down to earth for a bit? >> down obviously, and for novo, looking at where they have been in the last, i don't know, five months or so, it's down almost half, which is, if it weren't so big, it would be a takeover target for somebody, but it is, and still like, i don't know, $350 billion or so. i mean, this is bad. i am long lily. clearly, you can't help but think, if that's happening to novo, you have to think lily is going to suffer the pressure as well. i'm still long, r

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbuster diabetes and obesity drugs ozempic and wegovy. both contain the key ingredient semaglutide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soar. sharon osbourne, chelsea handler, and elon musk have all publicly talked about taking ozempic or wegovy, and they've had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps, including tiktok. but it's not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining the weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: when i ask the scientists, they say the priority and mechanism will tell you that it's chronic treatment. my personal view is that we will als

novo is just sort of living in their world.oss margins and is up there with revenue growth with lilly. but i think the next stage in this is to buy the smaller players. i mean altimmune, which is sub 500 market cap. so be careful if you're playing that at home. but i think you're going to wind up seeing the smaller players who have great efficacy be gobbled up by these two larger players. >> respectfully, i disagree. i think part of this is like. >> talking to me. yes, because i left i left the stage. >> you guys want to take this outside? >> no. it's cold. >> but i do think you look at nba for a trade here. right. and kind of ride that momentum. i think that the medicare negotiations, you've seen a lot of negative headlines. and you look at the stock off 40%. i mean they are still a player here. even if it is a duopoly. it doesn't take much market share for you to have accretive outcomes here. >> all right. there is a lot more fast money to come. here's what's coming up next. >> crypto cruising toward new highs as president tr

novo nordisk shares are jumping in today.plain why in the markets next. >> hey. >> thinking about retirement. would you like to have retirement income that you can count on for the rest of your life? how about up to 33% more income? call this number to get this free book annuity do's and don'ts for baby boomers. this book is filled with valuable information uncovering little known secrets to help you maximize your income in retirement and its free retirement income. you can count on starts by calling for this free book. as a bonus, we'll also rush this annuity rate report. also, absolutely free annuity national researched numerous products and summarize the rates and benefits of annuities from foremost insurance companies like nassau life and annuity call for both these free books. annuity national retirement income you can count on for the rest of your life. call now for your free books. call 800 211 4470. that's 800 211 4470 800 211 4470. >> people everywhere are losing weight with life. md. >> and i'm keeping it. >> off wi

francine: this is the man of -- in charge of novo nordisk and its blockbuster diabetes and obesity drugs, ozempic and wego v. both contain the key ingredient semi-glue tide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soared. sharon osbourne, chelsea handler and elon musk have all talked about publicly taking ozempic or wego v. it's a global phenomenon reaching millions on social media apps, including tiktok. but it's not without controversy including possible side effects, high prices on the company's lobbying for seen criticism around the world. in some cases patients might need to take the drugs indefinitely to avoid regaining the weight. the chief executive says obesity is a disease and think the company will learn from its growing number of patients. >> my personal view is that we will also feel that taste -- patients are -- much different and will be different. so there will have to be a portfolio of inventions. francine: i travel to the firm's headquarters in copenhagen, denmark. i asked lars about the global se

novo nordisk, trading at august 2023 lows. it's lost nearly half of its value since late june. >>> and viking thera sank. that is currently in midstage trials. for more on all of this, angelica peebles joins us. angelica? >> a, mel. that's right. lilly's fourth quarter coming up short of expectations. and that is renewing fears that it might also be slowing. >> because of supply tight accident in the first half of the year, inventory levels rose because of uncertainty. as we become a more predictable supplier, people able to work down their capital. and patients can get the medicine they want. >> lilly's new ceo. what they did there was they took the trends that they were seeing earlier in the ear when supplies were tight. and people started pulling back. they weren't ordering as much as they needed or that they were before because there was more supply available. and also learned that there is more seasonable stock available. saying there were just a few things that were a little bit out of whack in those guidance. and some o

how do the charts look, novo in particular?ouble here. i can come up with a $600 target. it's been topping for the better part of a year now. i think merck actually might be interesting long. you've had the pretty devastating bear market there. 100 has been very long-term support for many, many years. wouldn't be shocked if that bottomed here. >>> coming up, act natural. nat gas outperforming crude, and chris has his picks for some underowned names just bursting with energy. hipis,exs ck nt. more "fast money" in two.. ions. because a dog at a healthy weight could live a longer, happier life. i had the worst dream last night. you were in a car crash and the kids and i were on our own. that's awful, hon. my brother was saying he got life insurance from ethos. and he got $2 million in coverage, all online. life insurance made easy. check your price today at ethos.com. your shipping manager left to "find themself." leaving you lost. you need to hire. i need indeed. indeed you do. spsored jobs on indeed are two and a half times fast

and look at the way novo and lilly have created specifically novo over the last, i don't know, 6 to 9topped out. and those looked a lot like some of these generative ai stocks or specifically like nvidia. so i look at a novo nordisk, if you tell me that you're not going to have any major competitors in the next year or so, trading at about 22 times this year's expected earnings growth at 22%, i know they've already got it down. maybe they've de-risked in the near term, but maybe that one looks more interesting. but i think they're both really tough right here. >> yeah. i mean, just to dan's point, think about how long it's been since they've made the simple thing of a 52 week high, right? so novo peaked at the last week of june. really in the second week of july. so you have the sort of one two setup of great preceding outperformance. and then now half of year and more of underperformance. that's usually it looks like this, right. yeah. not not great. >> i think there's also the issue that we saw with eli lilly's past two earnings releases, when they were talking about inventory and h

novo nordisk posted a really strong early trial results for one of its experimental drugs that showed patients can lose more weight versus previous drugs. keep in mind, stocks -- the stock is down by 14% over the past 12 months. it's a long way to recover. scarlet: good stuff. natalia kinazhevich thank you for the numbers. we are still waiting for the first trade from a venture global. that stock, when it does begin trading is under the ticker vg. another currency market all strength has been a theme since the election of donald trump with the bloomberg dollar index of more than 7% fourth quarter alone. earlier today jay polaski of tbw spoke about the currency's importance. jay: the dollar is key for us. if the dollar rolls over it is bullish on the exposure for 20 25. american exceptionalism at risk. there is no room for mistakes and in the u.s.. that is the main take away. there is room in the rest of the world. so, that audibled anova suggests to us -- the dollar rolling over suggests to us, where are there opportunities elsewhere? scarlet: morgan stanley has a note out focusing on

last, i'm looking at shares of novo. the u.s. is planning to slash what it pays for these drugs.than $200 billion in a decade. treatment for obesity and diabetes really leading the list of medicines that will be targeted under legislation that will encounter price negotiations over the next year. this is a part of the biden administration's effort to reduce costs for medicare. rivals will not be eligible for negotiations until 2029. it is unclear whether trump will respect or honor the list but novo nordisk is scheduled to report earnings next month. for now, shares lower by 5%. sonali: thank you, isabel lee. homebuilders have been moving in the session. today we got u.s. housing data showing new construction in december climbing at the fastest pace since early 2024. all of them ripping quite a bit. we will talk real estate with bess friedman. stick with us for that conversation next. this is bloomberg. ♪ sonali: new u.s. economic data today showing housing starts in the u.s. climbed in december to the fastest pace since early 2024. for more on the real estate market as rates sta

ultimately, the big expansion and gain for novo nordisk was back in the day when they actually announced first progress with glp-1 drugs. is this now being capped? >> the concern is lily will take share. the glp-1 was disappointing. eli lilly was up 5%. the concern around not concern with obesity market. it is novo nordisk will lose share to eli lilly and their drug is not as good as zepbound is the marketing name. i disagree with that. i think generally speaking, it will still remain a duopoly. one in eight american adults is on glp-1 drugs. we expect that to continue. with that view to continue the glp-1 market is healthy and still a duopoly. the idea of losing share to eli lilly is overton. the valuation is low with the huge penetration growth story in america in particular and health insurance in europe will start covering this as well. super exciting. >> i guess they are trying to see if there are any other areas to advance via the glp-1 drugs. thank you for your time. the head of equities at fulcrum asset management. >>> meanwhile, russian gas ex-ex- s to europe via ukraine have st

we are particularly seeing novo nordisk under pressure within the healthcare space.et's see what will happen there as well. now, one of the main focus for the investors no doubt is the upcoming eurozone. we had the french coming in at 1.8% on the year in december. that is slightly higher than the 1.7% recorded in november. we have at the moment euro tracking higher against the u.s. dollar. we are up .40%. this continuing the moves we had witnessed already on monday, but all in all, i would like to dig deeper and understand the dynamics. charlotte, the figures are coming at a time when the new government trying to decide on fiscal policy. any clarity there? >> we will see. there could be some positive news for the month on december. it is a slight uptick on november. 1.8% against plus 1.7% in november. it was still very much below that ecb target of 2%. that is a different picture from other countries like germany or spain. some positive news. this is a bit of caution for the ecb for the next step. a slight rebound in energy prices and slight uptick in december which

forget that novo is down so much. anything they put out, they can say, hey, listen, this thing causes, you know, it, like, makes you feel better. it wouldn't matter. what matters is that that monjaro and weekly scripts are finally, finally doing good. and they had been not good. >> for a lot of discussion about how it's. >> hard to find. >> this kind. >> of top. >> tier growth in europe anywhere else. >> it is. and yet we've europe is much discussed as being doing well because the rates are so low in germany. >> but bouncing. >> up. >> against all time highs. >> all week. >> i know in japan rate hikes come, we're in a good time. and yet of course you have to have everyone saying well it's over. it's stretched, it's stretched. it's been stretched now. since when? since august of 1981. when i started, it was very stretched. right. you know, it went up like 80 points in like five weeks. it was stretched. i am just saying, don't play that game. find good stocks. find stocks that are winning and they're going higher. nvidi

novo in particular because now the news is official that novo's obesity drugs will be included in the medicare negotiating program, this was under the inflation reduction act which dictated that medicare could negotiate drug pricing for certain popular drugs. that potentially limits the upside on what is a very expensive -- what is it, $1,000 a month drug? >> i think there are a lot of people who felt that this had to happen. david ricks would be one of them, the ceo of lilly. i think that if you don't have comorbidities with these it's going to be difficult. you talk about $8 billion, maybe for novo and lilly's drug is superior in terms of weight reduction at the same dose. >> yeah. >> no one thought they would be able to just run amok and i think that while the stocks are down it's going to be the greatest drug of all time and everybody knows that. the persistence level of people who take it is much higher than what we're hearing about. drug and exercise have -- exercise has failed us, okay? diet has failed us. so drug is the way to make it so that people who -- >> well, now it will

so keep an eye on novo.or the fourth quarter. that was much worse than analyst estimates. the company attributed it to charges at its defense and commercial units, and ongoing effects from the big labor strike that boeing had, which has not posted, by the way, an annual profit since 2018. it's also scheduled to report earnings on tuesday morning. so boeing shares are off about 1.5%. and we'll finish with semiconductors, specifically analog chips. texas instrument shares are down just about 4.5% right now after it issued a weaker profit guidance number and said that the auto end market in the us, japan and europe continues to be weak. they did, though, beat on the top and bottom line for the quarter, but revenue still fell about 2% on a year over year basis. and mike, you and i both know this particular company is seen as somewhat of an economic bellwether, just given the fact that all of their chips go into just about everything in the market these days. so we'll keep an eye on txn. i'll send things. >> back

so keep an eye on novo nordisk up big and another one moving in the opposite direction. today is a name that we often talk about with semiconductors, but not so much like in the in the nvidia scope of things. but texas instruments is off 7%. it's down about $14. this is on the heels of better than expected earnings and profits revenues. everything is good. but the forecast came into question a little bit. it fell below some analysts expectations. and the reason why much of that is due to automotive end market weakness in places like europe, the us and japan. that's the reason why analog chip companies alongside texas instruments are also lower. and kelly. some traders and investors do look towards companies like texas instruments as a general economic bellwether globally, because those analog chips are used in everything from cars to washing machines to guided missile systems. so keep an eye on txn. i'll send things back over. >> to. >> the doctor. copper indicator. >> i like. >> the way that one's. >> going, dom. >> thanks. >> president trump wants the. >> federal reser

i'd like to do the same thing for novo nordisk. if you do get good news from novo nordisk, get this. you might want to buy some eli lilly before it reports on thursday. after the close wednesday, we hear from ford motor. ford has been a disappointment, largely because of warranty costs, things that went wrong. but with long term interest rates high and likely going higher, their sales could be stalling. the stock's been awful, so there's limited downside at these levels i question the upside. thursday more drugs. yes this is a tough drug week or or four mentioned eli lilly reports. while ceo david ricks announced here on cnbc the 2025 will be a good year. we got to get some more details before we plow in. i remain steadfast. we have big position for the trust. next. another trust holding bristol-myers. they got a whole series of great trucks, but the one people are watching very closely is coborn's. that's the first new class of schizophrenia medications in 30 years, far fewer side effects than the current standard of care. if real

we continue to own that stock. >> what about novo nordisk? this was interesting.nk this is not going away. if you look at the secular drivers behind obesity and the need for these drugs, it's not going away. more importantly, i do think while they may take a short-term revenue hit in terms of lowering price, i think they could gain a significant amount of market share. also, despite the huge obese population, there is an equally large population that does not want to become obese and there is a massive movement towards micro dosing. so i actually think this can still be a relevant drug in that world. >> thank you, appreciate it. >> before we go we'll call it an rbi, random but interesting. i know it's going to be super cold in d.c. for the inauguration. look at hotel prices. we looked on booking.com for sunday to tuesday. it's like $1,000 a night for a hotel that normally would be like $120 a night. we just talked about cars and sufficient costs. suv costs. well hotels for the inauguration in d.c. what else can i old man yell about this week? >> it's a sign of int

wednesday, earnings from disney, ford, chipmakers, and novo nordisk. thursday amazon and a bank of england decision. friday, job important consumer sentiment. and that headline out of reuters. the plan for trump to announce tariffs that will begin march 1. but no decision is final until the public announcement is made. we are watching markets on the heels of the news. for now that does it for us for your same time, same place next week. this was bloomberg real yield. this is bloomberg. >> potential u.s. tariffs tied to canada and mexico but the timeline is shifting. the original deadline is extended to march 1. equities rise. nasdaq leading the way. bonds, little change. gains

. >> share s of novo nordisk falling.f prescription drugs that potentially will be subject to medicare price negotiations. the negotiations are part of biden's inflation reduction act which gave medicare the power to directly hash out drug prices with manufacturers. you can see shares of novo down 5%. eli down almost 3%. goldman sachs paying ceo david sullivan $80 million to stay put for at least the next five years. $80 million. the board also plans to raise the ceos pay by 26% up to a whopping $39 million. this according to a new filing. shares of goldman sachs are up 2% on the notion he will be at the helm for the next five years. >> stability at the top, i guess the market is happy to see. thank you very much. we're also tracking shares of salesforce today. seema modi with more on that stock's move. >> reporter: hey, mike. analysts at cowen raising their earnings estimates after conducting an extensive survey on how companies are thinking about artificial intelligence budgets going into 2025. and they found that sales

novo nordisk's stock is not taking this well, shares dropping the a 52-week low of $78.87.a chop of about 5%. other names on the list include pfizer's advanced breasts asthma treatment, trely, and ab i have's it until bowel medication. it did give medicare the power to directly hash out drug prices with manufacturers, but it's unclear whether president-elect trump will change or try to scale back some of the law's provisions. trump has in the past said that he supported a path similar the what the biden administration has just taken. >>> let's look at corvo. remember when i told you intel was second best on the intel? -- on the s&p 500? starboard value revealed it has amassed a half billion dollar stake in the chipmaker. filings show starboard now owns 7.7% of corvo which makes radio frequent is city chips -- frequency chips. corvo's stock has been a laggard over the past year, losing about 29%. and she's barbie tough. in the wake of her wildly successful barbie movie, director greta gerwig has gotten netflix to agree to a first. her next film, narnia, based on the c.s. lew

performing sectors and up by more than 1% and one of the reasons behind this is the performance of novo nordisk. 1.3% higher in industrial. in terms of the worst performing sectors. let's get a check on that too. telecoms is down 0.4%. food and beverages also under a little bit of pressure. however, not, you know, not sufficiently lower for the time being. but over now though back over to you, dan. >> thanks for the update. coming up on the program, we are going to hear from the swedish finance minister and bring you that interview live next for you right here from davos. >> some people. >> like doing things the hard way, like doing their finances with a spreadsheet instead of using quicken. quicken pulls all using quicken. quicken pulls all your financial info together in hey, can you speak french? who, me? i know a few words. if you're struggling to speak a new language, you should try babbel, a learning platform designed by over 200 language experts. it's like having your own personal language coach. babbel offers live classes with expert teachers for real world conversation practice

novo nordisk, look at this stock, you guys.eporting positive results from the new obesity drug. early stage trials showing weight loss of up to to 22 president matches the number of zepbound which is made by rival eli lilly. >>> intuitive surgical slipping in spite of its upbeat fourth quarter report, issuing lackluster gross margin guidance for 2025. still, citigroup raising its price target from 640 up to 711. deutsche bank upping theirs from about 505 to 585. and one of the big stories of the day, meta's ceo, mark zuckerberg, saying his platform wills invest as much as $65 billion this yearal to expand the a.i. infrastructure. the investment will include building a 2-gigawatt data center and ramping up hiring for a.i. positions. the social networking company also announcing that it will begin limited early testing on its threads app with a handful of brands in the u.s. and japan. and we also just want to say that $65 billion blew away analyst expectations for, like, $50 billion in cap-x, so the spending continues. >>> all ri

minnesota que dependen de la insulina, ahora podrÁn comprarla por 35 $ al mes gracias a un acuerdo con novoÉ nuestro cuerpo produce tanta mucosidad? borja: Éste es un tema de salud no sÓlo para nosotros, sino para toda la familia. hoy queremos conversar con la doctora juanita mora, portavoz de la asociaciÓn americana del pulmÓn, para que nos ayude a entender un poquito mÁs sobre este proceso. y algo importante que pocas veces se habla, el papel que juega la mucosidad en nuestro sistema inmunolÓgico. doctora mara, gracias por acompaÑarnos una vez mÁs aquÍ en la "ediciÓn digital". ¿por quÉ nuestro cuerpo produce mucosidad, y quÉ nos dice eso sobre el funciona mente de nuestro sistema inmunolÓgico? >> buenos dÍas. siempre un gusto . la mucosidad se produce mucho en respuesta que el sistema inmunolÓgico hace cuando entran cosas alÉrgicas, como el polen, el polvo, tambiÉn en respuesta cuando nos enfermamos, un virus que quiere entrar en nuestro cuerpo, una bacteria con los cambios de temperatura extrema, como el frÍo, el calor, ante esta sustancia gelatinosa para atrapar lo que es ese polen no e

david: there's another company in sort of the same business, novo nordisk. they have a similar product. they have a product that does the same thing. one is for obese tirk anti-obesity, one is for diabetes. is there really in difference in terms of the drugs? dave: there are. there's no real difference between the one for die beesby tees and anti-obesity, that's for insurance purposes. right now, because you just ate lunch your g.i. tract is communicating with the rest of the body, communicating with hormones and protein, saying you've been fed uric need to absorb knew trepts and other things that are see en-- essential to life. what we're doing is boosting some of those signals with these medications. they're boosting the signal that you're full. boosting the signal that you no longer want to eat more. boosting signals that you should absorb nutrients you have consumed. our does that with two different hor moans. one, glp-1 and another g.i.p. osemp i think -- ozempic or semaglutide does similar. david: so it affects the way you feel? >> as people eat more h

all the averages are up about 2% for the week though novo nordisk shares are jumping. the trial for a new weight loss drug showed success 22% body weight loss in an early trial covering 125 people. those shares are up 8%, though they're still down 16% on the year. and quantum is back in the news. rigetti is the most actively traded stock on the new york stock exchange today. it's up 3% today, 40% this week, almost 14 a share and flattish on the year after a big drop from those jensen wong comments when he questioned when quantum brian would actually arrive. >> well, the four pizzas we had for lunch as a show, not in that novo nordisk study. all right, kelly, thank you. we've got a lot more to do this hour, but let's start here with some news in retail. as one of america's biggest retailers just decided to back away from some dei initiatives. cnbc retail reporter melissa repko is here with more on that melissa. >> so target said today that it's backing away from some major dei programs, including pledges it made after the police involved. >> murder of. >> george floyd a

novo is also studying a pill version.will have company during the super bowl halftime show. he revealed that frequent collaborator sza will join him during his super bowl performance. this will mark sza's first appearance during the halftime show, but lamar debuted alongside mary j. blige in 2020 two, and snoop dogg, dr. dre ,eminem, and 50 cent. and great i believe he got best -- annmarie: i have seen kendrick lamar in person and am a fan of sza. this will be an exciting halftime performance. dani: unfortunate for drake. drake has lost the battle. kendrick lamar is reigning supreme. i am excited. and rape first -- annmarie: first rapper to be awarded that prize. pres. trump: investing in $600 billion in america from saudi arabia. and i will ask for that to be rounded out to run $1 trillion. annmarie: $1 trillion maybe coming from riyadh. that is next. you are watching "bloomberg surveillance." ♪ investment opportunities are everywhere you turn. do you charge forward? freeze in your tracks? or, let curiosity light the way

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbusters and obesity drugs ozempic and wegovy.

david: there's another company in sort of the same business, novo nordisk. which is in denmark. they have a similar product. they have a product that does the same thing. one is for obesity -- anti-obesity and one is for diabetes. is there really in difference in terms of the drugs? dave: there are. there's no difference between the drugs nature diabetes and obesity for either company. that's for insurance reasons. tirzepatide is one of them. it has two modes of action. right now, because you just ate lunch your g.i. tract is communicating with the rest of your body. it is communicating with hormones and protein, saying you have been fed and need to absorb nutrients and other things that are essential to life because food is essential to life. what we're doing is boosting some of those signals with these medications. they're boosting the signal that you're full. boosting the signal that you no longer want to eat more. boosting signals that you should absorb nutrients you have consumed. ours does that with two different hormones. one called glp-1 and another called g.i.p. ozempic

novo is down nearly 2%, and the matchup for super bowl 59 is set.chiefs of kansas city, who are going for a record third straight super bowl win. joining us now is two time super bowl mvp. former new york giants star quarterback eli manning. he's at the eye connections global conference in miami beach. eli we're all new jersey people. we could have done this here and saved you the trip. >> i know i should have known, but it's great to be down here in miami, get a little warm weather. >> get away. >> from the cold. so i'm enjoying. >> the conference. >> here at ai connections. >> absolutely. so i confess i watched it a little bit on sunday, but then i see all this drama on social media around the refs and the calls. did something really happen that we should be concerned about, or do you think this is just like sour grapes? >> yeah. >> i. >> think it was a great game. >> especially against the bills and the chiefs. both of these teams are deserving to be in that game. >> both of them could. >> have been deserving to make the super bowl. there's alway

network r t international, as well as russia's channel one television, and the news agency rianne novo speed not move, reflects the use ongoing. the suppression of diverse narrative that needs intolerance towards russian perspectives demonstrating its inclination to control information rather than uphold the freedom of speech. moscow said that the use action will not. ready unanswered and it will turn to international organizations for an adequate response. now we've heard from greg symonds, an independent, political research that they used in sweden. and he said europe results to censorship because it's losing the information war. so the roles based all the by like the routing was and the only reason they will be doing this is because of the losing view of somebody was so the tri state of the information so that it receives those very cheap and not very incredible wisdom and propaganda because the communication is coming from the globe themselves, including russia, a just to pretty much handle the golf is ridiculous, speak with one voice, which is or well in them itself. the ends, but

we will have interviews with the ceo of novo nordisk and eli lilly and merck.rldwide exchange." "squawk box " starting right no. have a great day. >>> good morning. breaking news from the middle east. negotiators are nearing a deal on the gaza cease-fire. details straight ahead. >>> china officials are reportedly considering a sale of u.s. tiktok business to elon musk as one possibility if the supreme court, in fact, upholds a ban. >>> and starbucks is reversing its open-door policy. it will soon require a purchase for people to hang out in caves or use the bathroom there. it's tuesday, january 14th, 2025 and "squawk box" begins right now. >>> good morning, everybody. welcome to "squawk box" here on cnbc. we are live from the nasdaq market site in times square. i'm becky quick along with joe kernen and andrew ross sorkin. and so far there are some green arrows this morning. actually, pretty decent advances if you are watching the dow up 150 points. nasdaq is up 150 points. the s&p indicated up by 30. yesterday was an interesting session to watch. we were under

thought that was interesting given denmark's biggest export to the united states is actually ozempic via novo nordisk. tom: one feels these stories have further to run. kriti gupta with a write-down on what we have been hearing from president trump. u.s. stocks got hammered yesterday, as a selloff in the world's biggest bond market deepened on speculation the federal reserve will not cut interest rates now until july, amid inflation risks. let's dive deeper with bloomberg valerie tytel. the ism services, the jobs data, walk us through to the market reaction and the pushing back then of that next cut from the fed. >> it was all about this yields rise yesterday. hot economic data that took another like higher. it also has been having a global effect. in london, u.k. gilt market shaken by the treasury market. yes we have that hot economic data. we also have trump commenting that interest rates are too high. a little bit of i guess the fed coming under pressure from trump already, getting hints of that in his press conference yesterday.let's put this yields rise in perspective because we are very

stuart: fda is approved novo-nordisk to expand the use of kidney disease and expanding ozempic.g. what do you say? >> these are miracle drugs and glp-1s are successful and good diabetes treatments, and this dove tails with that. one of the main adverse effects of long standing diabetes is it damages the kidneys and glp-1 drugs shown to decrease the worsening of kidney functions. i question that casual weight loss, 20, 15rbgs 20 pounds should be a bit -- 10, 15, 20 pounds and we should be careful and i prefer lifestyle modification and they're a go to drug for don't and in addition to reducing cardiovascular resident and can long term didny damage. stuart: wonderful drug. dr. frank contacessa, see you again soon. we'll have the wednesday trivia question. it's coming after this. advil liqui-gels are faster and stronger than tylenol rapid release gels. ♪ also from advil, advil targeted relief, the only topical with 4 powerful pain fighting ingredients that start working on contact .. transportation is one of the largest contributors to global emissions. the world needs a better way

. >> i think itht will be okay, larry, we will have one novo and ge wt it on the first round.. >> charlie: do you share his confidence?n >> no.th tha because we have all seen this before. i help. >> johnson is right.ect the problem is whoever they elect if it is not.pe >> johnson, it will be speakerdi next and they will do it to the next guy and the next guy and the next guy. it is tos no end to this been an adult in the room to bring the parties together.t there is an inevitableha compromise. that is what happens when you have a small majority like republicans have. until they start acting like ahn unifiesod team, republicans will always be in trouble. >> johnson i hope he survives, buy wht it is a bullet to everyy who wants to support president trump. >> charlie: kaylee, do youable feel confident president trump will be able to rally republicans in the t house aroud getting something dones ca so>> republicans can start to addresi their agenda?ic >> i certainly hopane so.hn began,so republicans owe it to o american people in this case to reelecnt mike johnson. what is the gre

i have to say i was glad to see novo on the list.icare would pay for them all. when it comes to emotions they're riding high about middlemen and about rfk jr. the only ones who should be trembling are the pharmacy benefit middlemen and those who our food. i'm no fan of the middleman and i'm all in on rfk when he's talking about food. i hope he sticks to that rather than the vaccine stuff. he can really make a difference and strike a real blow against obesity, diabetes and food makers. it's a long four years, and for them, the pain hasn 't even started. >> coming up, cramer takes your calls and the sky is the limit. it's a fast fire lightning round. next. >> the club is really about empowerment. empowering you to own your money. italy. today you're the ceo of vodafone. what is your strategy and vision for the future? >> we are changing our culture to really focus on our customers. we need to acknowledge that change is hard, but if people understand it's for the right reason, then you get the power of the organization with you. >> the

. >> we are seeing all of the obesity names down like novo and viking.getting hit on this. a lot of outstanding questions hoar. >> appreciate you bringing that report for us. >>> ahead, meta shares are slipping in today's session, what is behind the drop and what it may mean for the rest of the social stocks as well. we are back on the bell after this break. >>> sector sort is sponsored by sector spider etfs. >>> visit us on the web at sector spiders.com. ah, this one lets me adjust the bass. add more guitar. maybe some drums. wow, so many choices. yeah. like schwab. i can get full-service wealth management, advice, invest on my own, and trade on thinkorswim. you know carl is the only frontman you need... oh i gotta take this carl, it's schwab. ♪ schwaaaab! ♪ have a choice in how you invest with schwab. your shipping manager left to "find themself." leaving you lost. you need to hire. i need indeed. indeed you do. sponsored jobs on indeed are two and a half times faster to first hire. visit indeed.com/hire that moment you walk in the office and people ar

are players that are not in the top two, for example, but even look at just the volatility even in novotwo trial for them wasn't exactly -- the numbers were great, but it wasn't exactly -- the bar is not only so high, but i think investors recognize that this isn't a two-horse race. >> yeah. in the fireside chat, the ceo was going to give a fireside chat when we were on the air. he talked, an interesting way he talked about it, we don't want to do a lot of discounting, coupons and things like that. we want to make sure we have the drug for our customers. this is a long-term relationship that we are building. we want to develop customer loyalty. sort of an acknowledgement that there's the ability to switch amongst players, if there's another product out there that is delivering the results, and is accessionable. >> yeah, i think that was -- in my opinion, that was in response to what i think was the disastrous call a quarter or so ago. so, good for him. but to your earlier point, the fact that on today's tape, the stock was up a dollar, given the selloff we've seen, is disappointing. i'l

luxury good maker have rallied 8% so far this year and have grabbed the number one title from denmark's novoe former giant behind diabetes and weight loss drugs ozempic and wegovy that has fallen 8% year to date over concerns that the u.s. government will push for lower pricing of those therapies barclay says marvell technology and nvidia are leaders when it comes to picking a.i. chip stocks in 2025 the firm hiked nvidia's price target to $175 a share is at 137 and change right now, marvels $250 a share it's 224 in change, barclay says it expects total addressable market in the a.i. chip space to grow all the way through 2026, the world is watching today's inauguration along with america while the new commander-in-chief steam has been credited for playing a big part in the return of three israeli hostages over the weekend, many of the global issues remain, the ukraine war, the china threat, cybersecurity among them, one of the top tech investors in the nation is here to tell us how she sees trumps future foreign policies impacting defense stocks in the sector in catherine boyles is here on a

novo nordisk is up today. what's going on there?0% so they just came out with the latest results from one of the latest trials they have with a new weekly injectable weight loss drug. the results so far are good. the average weight reduction was about 22% in obese and overweight people, patients after 36 weeks. so again, once weekly injectable drug. one of the latest that they are putting out maybe to market. david: all right we had a couple of names report before the bell. i want to start with american express. taylor: revenue for the quarter and year up 9%, earnings per share up 16% for the quarter, year-over-year. more importantly they are guiding revenue growth of 8-10% next year and increasing the quarterly dividend by about 17%. david: the market i guess is selling the news with the market right? taylor: a little bit. this is a stock that and again i spoke with the ceo and what he said is you have a little bit of a pullback from small businesses last year, right? because inflation and interest rates, small businesses have a ha

. >> happy new year from luanda angola feliz, ano novo. and the fireworks are up in the sky. it's all going down. three, two. >> one. happy new year! >> happy new year from london. wow! >> we had so much freaking fun. i love it. all right. to this now big ben striking midnight with its unforgettable chimes was resonating across london, especially as we rang in 2025. cnn's isa suarez went behind the scenes of the world's most famous clock to see just what it takes to keep that 165 year machine running on time, big ben. >> yeah. what does it sound like to you? you want me to imitate it? yeah. oh, no no no no no. ding dong, dong ding ding. bom bom ding dong ding dong. that's good. that's very good. that's the one. prepare yourselves for this moment. london. >> the old metropolis has been having a lot of fog lately. >> for 165 years, the bongs of big ben have kept londoners on time, consistently ringing in the changes. big ben is a favored spot for social media users. but one night a year, the bell and its bongs get a much bigger audience. it's now impossible to imagine a new yea

what can you tell me about novo nordisk and their latest obesity drug trial?'m surprised by the market reaction because a few of the headlines. semaglutide. the active ingredient achieved a 20.7% weight loss in obesity trial so basically achieved that primary endpoint by demonstrating significantly significant weight loss, relative to a placebo, right? so within 72 weeks, a higher dose, people lost about 25% of their weight loss. smaller dose? people lost about 17% of their weight. placebo, obviously you lose 0% of your weight so it met the endpoint but again, you know, a decent trial from what we hear. we'll have to dig into see what analysts say about it. stuart: stock is down 3.9%. palantir investing in a new drone start-up company. i believe the company is called shield a.i. what do we know? taylor: they are trying to raise about $200 million but would give shield a.i. a valuation of about $5 billion. so this is sort of classic tie-up where this aligns perfectly with palantir's idea, right? incorporate a.i. into the defense sector. it's not just palantir.

it made it possible to be able to take the de novo requirement and be able to put it into effect so the district judges would have something to go on. all these years -- and eventually he got most of the report but he didn't get the recommendations. of course if you read the report, you can tell what the recommendations are because that's factual material. 16 conclusions, you don't have to be a genius and who cares what they actually recommended, we want to know what the facts were. this was a great result. another case we had, we represented carl stern. carl at the time was the nbc reporter for the supreme court. and he had gotten wind of a little operation that j. edgar hoover had been running called co-intel pro. and carl came to us because the nbc at the time, when television networks were very important, could not afford to spend the money, chose not to spend the money, on hiring their own lawyers for the case. so he came to us to do a case pro bono. ron handled the case himself. he got before the district court and the defendant was the f.b.i. several important things happened whi

ozempic and wegovy are made by novo nordisk, which is based in denmark and has u.s. headquarters in plainsboro, new jersey. >> providing some comfort to firefighters and law enforcement in southern california, we'll introduce you to two pups whose mission it is to help those impacted in disaster zones. [music] >> plus, president elect trump will take the oath of office on monday and rebecca castor in washington with a look at how the nation's capital is preparing for the inauguration. >> coming up and giving you a look there at the mostly cloudy day over the golden gate bridge. it's a cooler one for most. i'll have a look at the current bounced from one doctor to the next. does it have to be like this? at kaiser permanente, we have a different kind of healthcare... so, how did you like doctor lum? ...where all of us work together for all that is you. elect donald trump. security is top of mind too, but the event is also being moved inside due to the weather. rebecca castor has the latest from washington with an arctic blast on the way. >> feels like temperatures on m